

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** ( Not for submission under 37 CFR 1.99)

Application Number	10700143
Filing Date	2003-11-03
First Named Inventor	Robert M. Lorence
Art Unit	1648
Examiner Name	N. Kinsey
Attorney Docket Number	18029

## **U.S. PATENTS**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

## **U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1		A1			

If you wish to add additional U.S. Published Application citation information please click the Add button.

## **FOREIGN PATENT DOCUMENTS**

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/NK/	1	2005/013920	WO	A2	2005-02-17	Bamat, et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

## **NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10700143
Filing Date	2003-11-03
First Named Inventor	Robert M. Lorence
Art Unit	1648
Examiner Name	N. Kinsey
Attorney Docket Number	18029

/NK/	1	Goeke, et al., " Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cipl", Digestion, 2001, Vol. 64, No. 2, pages 75-80. XP-002409571	<input type="checkbox"/>
↓	2	Krishnamurthy, et al., "Differentially Regulated Interferon Response Determines the Outcome of Newcastle Disease Virus Infection in Normal and Tumor Cell Lines", J. Virol. (June 2006) 80(11): 5145-5155.	<input type="checkbox"/>
	3	Horvath, "Newcastle Disease Virus: Its Oncolytic Properties" in Viral Therapy of Human Cancers, Sinkovics and Horvath eds., (Marcel Dekker, New York 2005) Chapter 5, pp. 533-574.	<input type="checkbox"/>
/NK/	4	McCormick, "Carcinoid Tumors and Syndrome", Gastroenterology Nursing (2001) 25(3): 105-111.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Nicole Kinsey/	Date Considered	06/13/2007
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.